Results released in November 2023 for the former indication showed that the treatment significantly reduced the 10-year predicted risk of ASCVD, though the company has not stated plans to apply for an approval in this space
These two factors, when combined, could have a significant impact on long-term outcomes
Studies of bariatric surgery patients have documented similar phenomena, where rapid weight changes can temporarily exacerbate joint symptoms before eventual improvement occurs
For patients specifically seeking weight loss medication, Wegovy is the appropriate semaglutide formulation to consider, and the question becomes whether Medicaid covers weight loss shots like Wegovy in their state
Qualified providers interpret results alongside clinical assessment, prior medication experience, and metabolic markers to inform personalized treatment planning